Skip to main content
. 2015 Apr 1;2(6):595–608. doi: 10.1002/acn3.197

Table 3.

Summary of ability of antagonists to block αCGRP or rAmy-stimulated cAMP accumulation in neuron-enriched rat TG cultures and Cos 7 cells transfected with rat or human CGRP receptor components

Rat TG neurons Rat CLR/RAMP1 Rat CTR/RAMP1 Human CLR/RAMP1 Human CTR/RAMP1
rαCGRP hαCGRP
 AC187 7.54 ± 0.36 (3)*** <6 (4) 8.21 ± 0.57 (3)** <6 (4) 8.22 ± 0.16 (4) *,++
 Olcegepant 7.79 ± 0.21 (6) *** 7.95 ± 0.12 (4) *** <6 (4) 9.65 ± 0.26 (5) 7.23 ± 0.14 (4)
 Telcagepant 5.72 ± 0.14 (4) 5.34 ± 0.14 (4) 4.17 ± 0.65 (3) 9.00 ± 0.17 (10) 7.36 ± 0.12 (3)
 rαCGRP8–37 8.12 ± 0.07 (5) *** 8.12 ± 0.27 (3)1 7.20 ± 0.16 (3)1 7.79 ± 0.14 (6)***,+++ 7.72 ± 0.18 (6)
rAmy
 AC187 8.07 ± 0.21 (4)+++ <6 (4) 8.06 ± 0.29 (4)***
 Olcegepant 6.26 ± 0.06 (3) 7.46 ± 0.16 (4) ** <6 (3)
 Telcagepant 5.84 ± 0.30 (4) 4.27 ± 0.31 (3)
 rαCGRP8–37 7.64 ± 0.18 (4)++ 7.07 ± 0.15 (4)1

Data are pA2 values, representing antagonist potency. Where pA2 values could not be determined they are defined as less than the highest concentration of antagonist used. Data represent mean ± SEM of n individual experiments. Comparisons were performed by Student’s t-test or one-way ANOVA followed by Tukey’s tests. TG, trigeminal ganglia; CGRP, calcitonin gene-related peptide; CLR, calcitonin receptor-like receptor; CTR, calcitonin receptor; RAMP, receptor activity-modifying protein; –, not performed.

1

CGRP8–37 data in transfected cells as previously reported.20 Previously reported data were not included in statistical analysis.

Comparisons shown are against telcagepant (**P < 0.01, ***P < 0.001) or olcegepant (++P < 0.01, +++P < 0.001).